Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups

Cancer medicine

Volumn 3, Issue 3, 2014, Pages 555-564

  Cuneo, Antonio ^a   Cavazzini, Francesco ^a   Ciccone, Maria ^a   Daghia, Giulia ^a   Sofritti, Olga ^a   Saccenti, Elena ^a   Negrini, Massimo ^a   Rigolin, Gian M atteo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

BCL2; chemoimmunotherapy; Chronic lymphocytic leukemia; genetic lesions; tyrosine targeted treatment

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; OBINUTUZUMAB; PROTEIN BCL 2; PROTEIN P53;

AGED; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HUMAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MUTATION; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84902091802     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.226     Document Type: Article

References (0)